Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. 2009

Raymond Tubbs, and William E Barlow, and G Thomas Budd, and Eric Swain, and Peggy Porter, and Allen Gown, and I-Ten Yeh, and George Sledge, and Charles Shapiro, and James Ingle, and Charles Haskell, and Kathy S Albain, and Robert Livingston, and Daniel F Hayes
Department of Molecular Pathology, Cleveland Clinic, Cleveland, OH 44195, USA. TubbsR@ccf.org

OBJECTIVE Amplification and deletion of the TOP2A gene have been reported as positive predictive markers of response to anthracycline-based therapy. We determined the status of the HER2 and TOP2A genes in a large cohort of breast cancer patients treated with adjuvant doxorubicin (A) and cyclophosphamide (C). METHODS TOP2A/CEP17 and HER2/CEP17 fluorescent in situ hybridization (FISH) were performed on tissue microarrays (TMAs) constructed from 2,123 of the 3,125 women with moderate-risk primary breast cancer who received equivalent doses of either concurrent adjuvant chemotherapy with A plus C (n = 1,592) or sequential A followed by C (n = 1,533). RESULTS An abnormal TOP2A genotype was identified for 153 (9.4%) of 1,626 patients (4.0% amplified; 5.4% deleted). An abnormal HER2 genotype was identified for 303 (20.4%) of 1,483 patients (18.8% amplified; 1.6% deleted). No significant differences in either overall survival (OS) or disease-free survival (DFS) were identified for TOP2A. In univariate analysis, OS and DFS rates were strongly and adversely associated only with higher levels of HER2 amplification (ratio > or = 4.0). Survival was not associated with low-level HER2 amplification (ratio > or = 2; OS hazard ratio [HR], 1.14; P = .39; DFS HR, 1.07; P = .62), but it was associated for a ratio > or = 4 (OS HR, 1.45; P = .03; DFS HR, 1.38; P = .033), in which analysis was adjusted for menopausal status, hormone receptor status, treatment, number of positive nodes, and tumor size. CONCLUSIONS In this population of patients with early-stage breast cancer who were treated with adjuvant AC chemotherapy, TOP2A abnormalities were not associated with outcome. HER2 high-level amplification was a prognostic marker in anthracycline-treated patients.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002886 Chromosomes, Human, Pair 17 A specific pair of GROUP E CHROMOSOMES of the human chromosome classification. Chromosome 17
D004250 DNA Topoisomerases, Type II DNA TOPOISOMERASES that catalyze ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. These enzymes bring about relaxation of the supercoiled DNA and resolution of a knotted circular DNA duplex. DNA Topoisomerase (ATP-Hydrolysing),DNA Topoisomerase II,DNA Topoisomerase II alpha,DNA Topoisomerase II beta,DNA Type 2 Topoisomerase,TOP2A Protein,TOP2B Protein,Topoisomerase II,Topoisomerase II alpha,Topoisomerase II beta,Type II DNA Topoisomerase,alpha, Topoisomerase II,beta, Topoisomerase II
D004268 DNA-Binding Proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. DNA Helix Destabilizing Proteins,DNA-Binding Protein,Single-Stranded DNA Binding Proteins,DNA Binding Protein,DNA Single-Stranded Binding Protein,SS DNA BP,Single-Stranded DNA-Binding Protein,Binding Protein, DNA,DNA Binding Proteins,DNA Single Stranded Binding Protein,DNA-Binding Protein, Single-Stranded,Protein, DNA-Binding,Single Stranded DNA Binding Protein,Single Stranded DNA Binding Proteins
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005260 Female Females
D005784 Gene Amplification A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication. Amplification, Gene
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Raymond Tubbs, and William E Barlow, and G Thomas Budd, and Eric Swain, and Peggy Porter, and Allen Gown, and I-Ten Yeh, and George Sledge, and Charles Shapiro, and James Ingle, and Charles Haskell, and Kathy S Albain, and Robert Livingston, and Daniel F Hayes
January 2012, Journal of translational medicine,
Raymond Tubbs, and William E Barlow, and G Thomas Budd, and Eric Swain, and Peggy Porter, and Allen Gown, and I-Ten Yeh, and George Sledge, and Charles Shapiro, and James Ingle, and Charles Haskell, and Kathy S Albain, and Robert Livingston, and Daniel F Hayes
August 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Raymond Tubbs, and William E Barlow, and G Thomas Budd, and Eric Swain, and Peggy Porter, and Allen Gown, and I-Ten Yeh, and George Sledge, and Charles Shapiro, and James Ingle, and Charles Haskell, and Kathy S Albain, and Robert Livingston, and Daniel F Hayes
May 2020, Journal of surgical oncology,
Raymond Tubbs, and William E Barlow, and G Thomas Budd, and Eric Swain, and Peggy Porter, and Allen Gown, and I-Ten Yeh, and George Sledge, and Charles Shapiro, and James Ingle, and Charles Haskell, and Kathy S Albain, and Robert Livingston, and Daniel F Hayes
August 2012, Annals of oncology : official journal of the European Society for Medical Oncology,
Raymond Tubbs, and William E Barlow, and G Thomas Budd, and Eric Swain, and Peggy Porter, and Allen Gown, and I-Ten Yeh, and George Sledge, and Charles Shapiro, and James Ingle, and Charles Haskell, and Kathy S Albain, and Robert Livingston, and Daniel F Hayes
January 2004, The oncologist,
Raymond Tubbs, and William E Barlow, and G Thomas Budd, and Eric Swain, and Peggy Porter, and Allen Gown, and I-Ten Yeh, and George Sledge, and Charles Shapiro, and James Ingle, and Charles Haskell, and Kathy S Albain, and Robert Livingston, and Daniel F Hayes
May 2020, Journal of surgical oncology,
Raymond Tubbs, and William E Barlow, and G Thomas Budd, and Eric Swain, and Peggy Porter, and Allen Gown, and I-Ten Yeh, and George Sledge, and Charles Shapiro, and James Ingle, and Charles Haskell, and Kathy S Albain, and Robert Livingston, and Daniel F Hayes
February 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Raymond Tubbs, and William E Barlow, and G Thomas Budd, and Eric Swain, and Peggy Porter, and Allen Gown, and I-Ten Yeh, and George Sledge, and Charles Shapiro, and James Ingle, and Charles Haskell, and Kathy S Albain, and Robert Livingston, and Daniel F Hayes
February 2012, British journal of cancer,
Raymond Tubbs, and William E Barlow, and G Thomas Budd, and Eric Swain, and Peggy Porter, and Allen Gown, and I-Ten Yeh, and George Sledge, and Charles Shapiro, and James Ingle, and Charles Haskell, and Kathy S Albain, and Robert Livingston, and Daniel F Hayes
February 2010, Orvosi hetilap,
Raymond Tubbs, and William E Barlow, and G Thomas Budd, and Eric Swain, and Peggy Porter, and Allen Gown, and I-Ten Yeh, and George Sledge, and Charles Shapiro, and James Ingle, and Charles Haskell, and Kathy S Albain, and Robert Livingston, and Daniel F Hayes
February 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!